Company Name : Trident Pharmaceuticals
Address : 184 High Street, Boston, MA 02110
Tel No: 011 44 7717 801296
Email : awatt@tridentpharma.com
Website : http://www.tridentpharma.com/
Company Profile
Trident Pharmaceuticals is dedicated to the development of novel immunomodulatory drug products for the treatment of autoimmune disorders and allergic diseases.
image of blood cells
The company’s lead drug candidate, HF1020, is an oral biopharmaceutical product which acts by modulating autoreactive T cells, including inducing antigen-specific regulatory T cells(Tregs), as a treatment for autoimmune disorders including rheumatoid arthritis, IBD and psoriasis, and allergic diseases such as asthma.
Existing standard of care for these autoimmune and allergic disorders predominantly involve the control of symptoms, with systemic anti-inflammatory and immunosuppressive agents forming the cornerstone of current treatments. However, induction of tolerance to self-antigens remains the goal for the next generation of immuno-therapeutics. To this end, Trident’s approach is to specifically control immunological tolerance. The goal with HF1020 is to develop an oral biopharmaceutical therapy which selectively modulates the aberrant immune response associated with autoimmune and allergic diseases without causing systemic immunosuppression.
HF1020 has been extensively evaluated preclinically, has shown efficacy in a wide range of inflammatory models, and successfully completed formal GLP preclinical safety/toxicology evaluation in two species. In a Phase Ia single-ascending dose clinical study, HF1020 was found to be safe and well tolerated in healthy volunteers. Trident is planning to commence a Phase Ib/IIa study in psoriasis patients to assess the safety and tolerability of multiple doses of HF1020 with concomitant evaluation of a number of inflammatory biomarkers as a preliminary indicator of efficacy.
Advent Healthcare Ventures is a co-founder and lead investor in Trident. Additional investors include Omega Funds and Brooke Private Equity.
